middle.news
Lumos Diagnostics Expands US Market with FDA CLIA Waiver, Triggers US$6.2M Milestones
10:12am on Monday 20th of April, 2026 AEST
•
Healthcare
Read Story
Lumos Diagnostics Expands US Market with FDA CLIA Waiver, Triggers US$6.2M Milestones
10:12am on Monday 20th of April, 2026 AEST
Key Points
FDA grants 510(k) clearance with CLIA waiver for FebriDx, expanding US addressable market to 80 million patients annually
Milestone payments of US$6.2 million triggered from PHASE Scientific and BARDA
Q3 FY26 revenue up 37% to US$4.8 million, driven by 243% growth in product sales
A$20 million placement completed; Share Purchase Plan underway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Lumos Diagnostics (ASX:LDX)
OPEN ARTICLE